• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Evidence for impact
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Evidence for impact
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > News

DNDi uses global mobile data service developed by FIND to manage clinical data in the Democratic Republic of Congo

Home > News

DNDi uses global mobile data service developed by FIND to manage clinical data in the Democratic Republic of Congo

Clinician looking into a microscope
18 Apr 2019

DNDi is piloting a global SIM card service designed by The Foundation for Innovative New Diagnostics (FIND) to send clinical trial data securely from several clinical sites in the Democratic Republic of Congo (DRC). SIMs are small cards containing chips that are used in mobile phones and other connected devices to transmit data over the Internet in a secure manner.

DNDi is using the global SIM cards to create portable Wi-Fi zones to enable the secure sharing of data in remote locations where connectivity is unreliable. Powered by cross-border mobile network operator Telecom26 AG, SIMplicity provides cost-effective and dependable mobile data capabilities for diagnostics and other connected healthcare devices, via global SIM cards. Where a Global System for Mobile communications (GSM) is available, the SIM cards are a less expensive alternative to putting satellite dishes at clinical trial sites to transmit data.

“This is a great example of product development partnerships (PDPs) working together to better record and track disease diagnoses in remote and low-resource areas,” said Pascal Carpentier, Head of Information Systems and Technology at DNDi. “FIND faces similar challenges to DNDi in transmitting data to and from places with limited connectivity, and we are benefiting from this new product that is in a nascent phase, while providing them with valuable information to help refine the service.”

The digital connectivity service, which was launched last year and specifically designed to support global health partners, is part of FIND’s commitment to developing and expanding access to connected diagnostic tools for poverty-related diseases. Healthcare programmes using locally purchased, pay-as-you-go SIM cards for connectivity in low- and middle-income countries may face issues such as deactivation, managing multiple subscriptions, and a lack of quality assurance and reporting mechanisms.

“This product gives us an immediate global answer to connectivity and we are looking at using it at additional clinical sites in Uganda and Guinea,” Mr Carpentier said.

Photo credit: Xavier Vahed-DNDi

Partnership Strengthening Capacities

Read, watch, share

Loading...
Statements
25 Sep 2026

DNDi intervention at the UN High-Level Meeting on Pandemic Prevention, Preparedness, and Response at the 81st UN General Assembly

Viewpoints
30 Sep 2030

How a one-day cure could finally eliminate sleeping sickness in Africa

News
15 Sep 2026

New DNDi report: Implementing Article 9.5 of the WHO Pandemic Agreement – building on current policy and practice for publicly funded R&D

Hand with lap glove holding a sample with transparent liquid
Publications
8 Sep 2026

Implementing Article 9.5 of the WHO Pandemic Agreement

Stories
27 Aug 2026

Drug discovery explained: Moonshot: open science to prepare for pandemics?

Pictures of patients waiting at the Mycetoma Research Center in Sudan
Stories
20 Aug 2026

Mycetoma at 10: What recognition made possible

Nature Africa logo
Viewpoints
3 Aug 2026

A new chapter for African medical innovation

Nature Africa
Viewpoints
30 Jul 2026

Ten years after WHO recognition, mycetoma remains one of the world’s most neglected diseases

Stat News
VIEW ALL

Help neglected patients

To date, we have delivered seventeen new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Linkedin-in Instagram Youtube Tiktok Facebook-f
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films, and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license